Bcl-2–regulated apoptosis and cytochrome c release can occur independently of both caspase-2 and caspase-9 by Marsden, Vanessa S. et al.
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
C
e
l
l
 
B
i
o
l
o
g
y
 
©
 
 The Rockefeller University Press, 0021-9525/2004/06/775/6 $8.00
The Journal of Cell Biology, Volume 165, Number 6, June 21, 2004 775–780
http://www.jcb.org/cgi/doi/10.1083/jcb.200312030
 
JCB
 
Report
 
775
 
Bcl-2–regulated apoptosis and cytochrome 
 
c
 
 
release can occur independently of both caspase-2 
and caspase-9
 
Vanessa S. Marsden,
 
1
 
 Paul G. Ekert,
 
1,2
 
 Mark Van Delft,
 
1
 
 David L. Vaux,
 
1
 
 Jerry M. Adams,
 
1
 
 and Andreas Strasser
 
1
 
1
 
The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria 3050, Australia
 
2
 
Murdoch Children’s Research Institute, Melbourne, Victoria 3052, Australia
 
poptosis in response to developmental cues and
stress stimuli is mediated by caspases that are regu-
lated by the Bcl-2 protein family. Although caspases
2 and 9 have each been proposed as the apical caspase in
that pathway, neither is indispensable for the apoptosis of
leukocytes or ﬁbroblasts. To investigate whether these cas-
pases share a redundant role in apoptosis initiation, we
generated caspase-2
 
 
 
/
 
 
 
9
 
 
 
/
 
 
 
 mice. Their overt phenotype,
embryonic brain malformation and perinatal lethality mir-
rored that of caspase-9
 
 
 
/
 
 
 
 mice but were not exacerbated.
Analysis of adult mice reconstituted with caspase-2
 
 
 
/
 
 
 
9
 
 
 
/
 
 
A
 
hematopoietic cells revealed that the absence of both
caspases did not inﬂuence hematopoietic development.
Furthermore, lymphocytes and ﬁbroblasts lacking both
remained sensitive to diverse apoptotic stimuli. Dying
caspase-2
 
 
 
/
 
 
 
9
 
 
 
/
 
 
 
 lymphocytes displayed multiple hallmarks
of caspase-dependent apoptosis, including the release of
cytochrome 
 
c
 
 from mitochondria, and their demise was
antagonized by several caspase inhibitors. These ﬁndings
suggest that caspases other than caspases 2 and 9 can
promote cytochrome 
 
c
 
 release and initiate Bcl-2–regulated
apoptosis.
 
Introduction
 
Apoptosis, which is critical for development and tissue
homeostasis, is executed by caspases (Adams, 2003). The 10
or so mammalian caspases include both “effectors” (3, 6, and
7), which efficiently digest vital proteins, and “initiators”
(e.g., 2, 8, and 9), which proteolytically activate the effectors.
Many cell “stress” stimuli, e.g., cytokine deprivation and
genome damage, and developmental cues, trigger a common
pathway of caspase activation regulated by the Bcl-2 protein
family (Adams, 2003). Until recently, the sole apical initiator
in that pathway was assumed to be caspase-9, which is acti-
vated in a complex termed the “apoptosome” by the scaffold
protein Apaf-1 and its cofactor cytochrome 
 
c
 
. Evidence that
the Bcl-2 family regulates permeabilization of mitochondria
argued that cytochrome 
 
c
 
 release and the ensuing caspase-9
activation were central to the “stress” response. For some
neuronal cells, this model is supported, as mice lacking
Apaf-1 or caspase-9 die perinatally with brain overgrowth
caused by a defect in neuronal apoptosis (Adams, 2003).
The apoptosome is not, however, universally essential for
Bcl-2–regulated apoptosis, because certain neuronal (Honar-
pour et al., 2001), hematopoietic, and fibroblastoid cells
(Marsden et al., 2002) lacking Apaf-1 or caspase-9 readily
undergo apoptosis in response to diverse insults and, at least
in lymphocytes, that apoptosis requires caspase activity (Mars-
den et al., 2002). Hence, there must be apoptotic pathways
regulated by the Bcl-2 family that require the activation of
caspases other than caspase-9 (Adams, 2003).
Evidence is also accumulating that certain caspases can
contribute to mitochondrial damage and hence may be
activated before apoptosome formation (Guo et al., 2002;
Lassus et al., 2002; Marsden et al., 2002; Robertson et al.,
2002). In particular, caspase-2 has been implicated in cyto-
chrome 
 
c
 
 release (Guo et al., 2002; Lassus et al., 2002;
Robertson et al., 2002) and seems to be necessary for cellular
demise in some transformed cell lines (Lassus et al., 2002).
However, because apoptosis is not markedly impaired in
caspase-2–deficient mice (Bergeron et al., 1998; O’Reilly et
al., 2002), caspase-2 cannot have a major nonredundant role
in apoptosis.
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These discordant findings might be reconciled if caspase-2
acts redundantly with caspase-9, each activating distinct but
converging pathways. If so, loss of both caspases should
markedly attenuate apoptosis. We address that hypothesis
here by studies on mice lacking both caspases 2 and 9.
 
Results and discussion
 
To generate mice lacking both caspases 2 and 9, we first inter-
crossed animals deficient in caspase-2 (O’Reilly et al., 2002)
with caspase-9
 
 
 
/
 
 
 
 mice (Kuida et al., 1998). As expected from
the severe caspase-9
 
 
 
/
 
 
 
 phenotype (Hakem et al., 1998;
Kuida et al., 1998), intercrosses of the resulting caspase-2
 
 
 
/
 
 
 
9
 
 
 
/
 
 
 
 mice yielded no weaned progeny lacking caspase-9, irre-
spective of caspase-2 status (67 progeny genotyped). Mice of
all other genotypes appeared at the expected Mendelian ratios
and were healthy and fertile (unpublished data).
To investigate whether caspase-2 deficiency exacerbated
the neuronal overgrowth characteristic of the caspase-9 defi-
ciency (Hakem et al., 1998; Kuida et al., 1998), embryos
from the intercrosses were examined at E14.5, when all ge-
notypes appeared in the expected ratios. Brain over-growth
resembling that previously described and observed in cas-
pase-2
 
 
 
/
 
 
 
9
 
 
 
/
 
 
 
 littermates (Fig. 1) appeared in 6/11 caspase-
2
 
 
 
/
 
 
 
9
 
 
 
/
 
 
 
 and 2/5 caspase-2
 
 
 
/
 
 
 
9
 
 
 
/
 
 
 
 embryos but never in
those expressing caspase-9 (
 
n 
 
  
 
47). All other organs ap-
peared normal. Although the brain abnormalities cannot be
quantified, we conclude that caspase-2 loss does not substan-
tially exacerbate the brain phenotype due to caspase-9 defi-
ciency and that other organs develop normally to at least
E14.5 without either caspases 2 or 9.
Bcl-2–regulated apoptosis, which is critical for the physio-
logical death of hematopoietic cells (Marsden and Strasser,
2003), can occur independently of caspase-9 (Marsden et al.,
2002). To study how caspase-2
 
 
 
/
 
 
 
9
 
 
 
/
 
 
 
 hematopoietic cells
respond to the physiological death cues in healthy mice,
C57BL/6-Ly5.1 mice were reconstituted with fetal liver–
derived hematopoietic stem cells from E14.5 offspring of the
intercrosses (Ly5.2
 
 
 
). 10 wk later, the thymocytes were all
derived from donor (Ly5.2) cells, irrespective of donor geno-
type (Fig. 2 A). The absence of caspases 2 and 9 did not aug-
ment cell numbers or perturb cell subset composition in the
thymus, spleen, lymph nodes, or bone marrow (Fig. 2, B–D;
and not depicted). Western blot analysis on reconstituted or-
gans (Fig. S1, available at http://www.jcb.org/cgi/content/
full/jcb.200312030/DC1) confirmed the absence of cas-
Figure 1. Loss of caspase-2 does not aggravate the overt defects 
caused by caspase-9 deficiency. (A) Similar overt phenotype of E14.5 
caspase-2
 / 9
 /  and caspase-9
 /  embryos. (B) Similar histologic 
presentation of caspase-2
 / 9
 /  and caspase-9
 /  embryos. Sagittal 
brain sections were stained with hematoxylin and eosin. For 
comparison, littermate embryos lacking only caspase-2, which are 
indistinguishable from wild-type embryos, are shown. O, oral cavity; 
B, basal ganglia; T, dorsal telencephalon; V, lateral ventricle; S, 
semicircular canals.
Figure 2. Normal hematopoietic development from caspase-2
 /  
9
 /  hematopoietic stem cells. Ly5.1 mice that had been lethally 
irradiated (2   5.5Gy) were reconstituted with fetal liver cells and 
analyzed 10–15 wk later. (A) Staining of thymocytes with antibodies 
to Ly5.1 (recipient) versus Ly5.2 (donor) cells. (B) Normal cellularities 
of thymus, lymph nodes (pooled inguinal, axillary, brachial and 
mesenteric), spleen and bone marrow in animals reconstituted with 
caspase-2
 / 9
 / cells. Results represent means   SD for  3 mice per 
genotype. (C) Normal composition of the thymus in the reconstituted 
mice. (D) Normal proportions of B lymphocytes (B220
  Thy-1
 ) and 
T cells (Thy-1
  B220
 ) in lymph nodes of the reconstituted mice. 
Results are representative of  3 mice per genotype. 
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pase-2 and/or -9 and revealed no compensatory up-regulation
of caspases 1, 3, 6, 7, 8, or 9. Thus, whereas overexpression of
Bcl-2 in the hematopoietic compartment, or absence of its
antagonist Bim, promotes cell accumulation (Bouillet et al.,
1999; Marsden et al., 2002), programmed death in that com-
partment appears unaffected by loss of both caspases 2 and 9.
To explore further whether caspases 2 and 9 are essential
for Bcl-2–regulated cell death, we analyzed the responses to
diverse cytotoxic insults of donor-derived B and T lympho-
cytes and CD4
 
 
 
8
 
 
 
 thymocytes purified from reconstituted
animals. The death on cytokine withdrawal of mature B or
T cells, activated T lymphoblasts or thymocytes was unim-
paired by the absence of caspase-2, caspase-9, or both (Fig.
3, A–C and Fig. S2 A, available at http://www.jcb.org/
cgi/content/full/jcb.200312030/DC1). Similarly, mature T
cells remained sensitive to dexamethasone (Fig. 3 A). In re-
sponse to 
 
 
 
 irradiation (Fig. 3 D; Fig. S2 B) or treatment
with dexamethasone, PMA, or etoposide (Fig. S2, C–H),
thymocytes lacking caspase-9 were slightly more resistant
than wild-type cells, but concomitant deficiency for caspase-2
provided no additional protection, and the lack of caspase-2
alone had no significant effect. This held over a range of
doses of each stimulus (Fig. S2, B, D, F, H; and not de-
picted). Thus, in lymphocytes caspase-9 deficiency at most
merely slows rather than prevents cell death, and concomi-
tant caspase-2 deficiency does not further reduce the rate.
To explore how loss of caspases 2 and 9 affected cells that
were not of hematopoietic origin, we studied embryonic fi-
broblasts lacking caspase-2, caspase-9, or both. When ex-
posed to etoposide, caspase-9
 
 
 
/
 
 
 
 fibroblasts died somewhat
more slowly than wild-type cells, but the protection was
transient and loss of caspase-2 provided no additional sur-
vival advantage (Fig. 3 E). Thus, caspase-2 deficiency does
not delay the death of caspase-9–deficient fibroblasts.
Dying caspase-9–deficient cells display the hallmarks of
apoptosis (Marsden et al., 2002). Concomitant absence of
caspase-2 did not prevent apoptosis. Two of its classic fea-
tures, exposure of phosphatidylserine and DNA fragmenta-
tion, appeared in caspase-2
 
 
 
/
 
 
 
9
 
 
 
/
 
 
 
 thymocytes subjected to
 
  
 
irradiation (Fig. 4, A and B). It is likely that effector cas-
pases contributed to their death, because the well-character-
ized caspase substrates ICAD, spectrin, and gelsolin (Fig. 4
C, Fig. S3, A and B, available at http://www.jcb.org/cgi/
content/full/jcb.200312030/DC1) were all processed appro-
priately, albeit to a lower extent than in dying wild-type
cells. ICAD is thought to be processed only by caspases 3 or
7 (McIlroy et al., 1999); caspase-3 is required to generate the
41-kD product of gelsolin (Slee et al., 2001), and although
either caspases or calpains can generate the 150-kD frag-
ment of spectrin, only caspases give the 120-kD fragment
(Methot et al., 2004). In dying caspase-2
 
 
 
/
 
 
 
9
 
 
 
/
 
 
 
 cells, all
three substrates yielded the expected caspase-dependent
products (Fig. 4 C; Fig. S3, A and B). Moreover, the gelsolin
processing was ablated in irradiated caspase-2
 
 
 
/
 
 
 
9
 
 
 
/
 
 
 
 thy-
mocytes treated with either of two structurally unrelated cas-
pase inhibitors, IDN-1965 (Fig. S3 C) or Q-VD-OPh (not
depicted). Thus, caspases are strongly implicated in the
death of these cells.
Processing of synthetic as well as physiological caspase
substrates is lower in cell lysates lacking caspase-9 (Marsden
et al., 2002). Similarly, with the fluorogenic caspase substrate
DEVD-aminomethylcoumarin, dying caspase-2
 
 
 
/
 
 
 
9
 
 
 
/
 
 
 
 or
caspase-9
 
 
 
/
 
 
 
 thymocytes had only 
 
 
 
10–20% of the DEVD-
ase activity of dying wild-type or caspase-2
 
 
 
/
 
 
 
 lysates, but
the activity was completely blocked by the caspase inhibitor
zVAD-fmk (Fig. S3 D). It was unaffected by ALLN, a po-
tent inhibitor of calpains and cathepsins, arguing against any
contribution of these proteases in processing this caspase
substrate.
To further explore whether the death of caspase-2
 
 
 
/
 
 
 
9
 
 
 
/
 
 
 
cells requires caspases, we examined the ability of four chem-
ically distinct caspase inhibitors to impair their death (Fig. 4
F). Three of them, Q-VD-OPh (Caserta et al., 2003), IDN-
1965, and IDN-6275 (Wu and Fritz, 1999), delayed apop-
tosis substantially up to 24 h after dexamethasone treatment
of T cells (Fig. 4 D). zVAD-fmk had a smaller inhibitory ef-
fect, probably due to its reportedly inferior stability, mem-
brane permeability, and performance in culture (Nicholson,
1999).
Non-caspase proteases, in particular calpains and cathep-
sins, have been proposed to contribute to apoptosis in cer-
Figure 3. Deficiency of caspases 2 and 9 does not prevent apoptosis 
in lymphocytes or fibroblasts. To test the sensitivity of lymphocytes 
to apoptotic stimuli, donor-derived (Ly5.2
 ) (A) lymph node T cells 
(Thy-1
 ), (B) lymph node B cells (CD45R-B220
 ) and (D) CD4
 8
  
thymocytes were purified from the reconstituted mice, or (C) T 
lymphoblasts were generated by mitogenic activation of spleen cells. 
(E) Early passage embryonic fibroblasts from E14.5 embryos. In all 
cases, viability was measured by staining cells with PI and FACS 
analysis. Results represent means   SD of  3 mice per genotype. 
778 The Journal of Cell Biology 
 
|
 
 
 
Volume 165, Number 6, 2004
 
tain circumstances (Jaattela and Tschopp, 2003). To deter-
mine whether either participated in the apoptosis of caspase-
2
 
 
 
/
 
 
 
9
 
 
 
/
 
 
 
 cells, we tested six inhibitors reported to impair
apoptosis under certain conditions: the calpain inhibitors
z-VF-CHO and PD150606 (Squier and Cohen, 1997), a cell-
permeable peptide of the natural calpain inhibitor calpa-
statin (Altznauer et al., 2004), the dual calpain and cathep-
sin inhibitors ALLM and ALLN (Ding et al., 2002), and the
selective cathepsin inhibitor z-FG-NHO-Bz-
 
p
 
OMe. In con-
trast to the caspase inhibitors, none of these inhibitors had
any anti-apoptotic activity at doses in the range where others
have reported efficacy (Fig. 4 D), and none cooperated with
IDN-1965 to enhance its antagonism of apoptosis (not de-
picted). Hence, it appears unlikely that either calpains or ca-
thepsins act in tandem with the caspase cascade to cause
apoptosis in these cells.
Cytochrome 
 
c
 
 release in thymocytes seems to depend on
caspase activity (Marsden et al., 2002), and caspase-2 has
been implicated in mitochondrial disruption in certain cells
(Guo et al., 2002; Lassus et al., 2002; Robertson et al.,
2002). Hence, we examined whether caspase-2 was the
sole caspase responsible for mitochondrial damage in thy-
mocytes. Western blotting of fractionated cell lysates re-
vealed that cytochrome 
 
c
 
 release from mitochondria did not
require caspase-2 (Fig. 5 A). Furthermore, mitochondrial
transmembrane potential in dying thymocytes was lost nor-
mally in the absence of caspase-2, or both caspases 2 and 9,
although its loss in wild-type thymocytes was attenuated by
a caspase inhibitor (Fig. 5 B), as shown previously (Bossy-
Wetzel et al., 1998). Hence, both the release of pro-apop-
totic molecules from mitochondria and the loss of mito-
chondrial transmembrane potential can occur independently
of caspases 2 and 9.
Our results strongly implicate caspases in the apoptosis of
caspase-2
 
 
 
/
 
 
 
9
 
 
 
/
 
 
 
 cells and thus imply that there is a Bcl-2–
regulated and caspase-mediated pathway that does not re-
quire either caspase-2 or -9. Which other caspases might be
regulated by Bcl-2? As discussed elsewhere (Adams, 2003),
caspases 1, 11, and 12 in mice (or caspases 1, 4, and 5 in hu-
mans) are attractive candidates, because, like caspases 2 and
9, their NH
 
2
 
-terminal CARD domain could interact with a
cognate scaffold to form an apoptosome-like complex. For
example, caspase-12, which is implicated in apoptosis in-
duced by ER stress (Nakagawa et al., 2000) and in cyto-
chrome 
 
c
 
–independent apoptosis (Morishima et al., 2002;
Rao et al., 2002), forms a large complex on serum starvation
(Kilic et al., 2002). In other systems, caspase-11 (Hisahara et
al., 2001; Kang et al., 2002) or caspase-1 (Hilbi et al., 1998;
Marsden et al., 2002; Rowe et al., 2002) have been impli-
cated in apoptosis. Hence, in different circumstances, vari-
Figure 4. Dying caspase-2
 / 9
 /  cells 
display hallmarks of apoptosis and are 
protected by caspase inhibitors but 
not calpain/cathepsin inhibitors. (A–C) 
Ly5.1
 CD4
 8
  thymocytes sorted from 
reconstituted mice were cultured follow-
ing 5 Gy   irradiation (ir.) (A) Staining 
with FITC-conjugated Annexin V plus PI 
reveals phosphatidylserine exposure 
before loss of membrane integrity irre-
spective of genotype. (B) DNA “laddering” 
indicative of inter-nucleosomal fragmen-
tation demonstrated by gel electrophoresis 
of genomic DNA. (C) Western blots 
showing processing of ICAD in dying 
caspase-2
 / 9
 /  cells. (D) The death of 
caspase-2
 / 9
 /  cells is antagonized by 
inhibitors of caspases but not of calpains 
or cathepsins. Ly5.1
 Thy1
  mature T 
lymphocytes from the lymph nodes of 
reconstituted mice were cultured for 24 h 
in the presence of 100 nM dexamethasone 
plus the caspase inhibitors zVAD-fmk, 
IDN-6275 (6275), IDN-1965 (1965), or 
Q-VD-OPh (Q-VD), the calpain inhibitors 
z-VF-CHO or PD-150606, a cell perme-
able peptide of the calpain inhibitor 
calpastatin, the dual calpain/cathepsin 
inhibitors ALLM and ALLN or the ca-
thepsin inhibitor z-FG-NHO-Bz-pOMe 
(zFG-NHO) (each at 50  M). Cell death 
was quantified by PI staining and FACS 
analysis. Results represent mean   SD 
of at least three independent experiments 
for each genotype. Vehicle: 0.4% DMSO.Apoptosis independent of caspases 2 and 9 | Marsden et al. 779
ous combinations of caspases 1, 11, and 12, and perhaps also
caspase-8, might act redundantly with caspases 2 and 9 to
initiate apoptosis.
Whereas our results with primary lymphocytes and fibro-
blasts implicate caspases in addition to caspases 2 and 9 in
the initiation of apoptosis, the accompanying paper, Ekert et
al. (2004) shows that the hallmarks of apoptosis failed to ap-
pear when myeloid progenitor cell lines lacking both cas-
pases 2 and 9 were deprived of growth factor, but that pro-
grammed cell death still prevented their clonogenic survival.
These findings and those with transformed human cell lines
(Lassus et al., 2002) can be reconciled with our conclusion
that caspases 2 and 9 are not essential for loss of viability per
se, if some cell types but not others use these caspases to ac-
celerate apoptotic cell demolition.
Materials and methods
Mice
Caspase-2
 / 9
 /  mice were generated by intercrosses of mice deficient in
caspase-2 (129/sv) (O’Reilly et al., 2002) with caspase-9
 /  (C57BL/6)
mice (Kuida et al., 1998). Embryos and 3-wk-old mice were genotyped by
PCR. Hematopoietic reconstitution was performed as described previously
(Marsden et al., 2002) from fetal liver cells of embryos with a caspase-2
 / ,
caspase-9
 / , or caspase-2
 / 9
 /  genotype (all mixed C57/BL6-129Sv,
Ly5.2
 ) or wild-type (C57/BL6 Ly5.2
 ) embryos.
Microscopic imaging
All microscopy used either a Stemi SV11 or an Axioplan 2 microscope
(Carl Zeiss MicroImaging, Inc.). The latter used objective lenses (magnifi-
cation/numerical aperture: 5 /0.15 and 10 /0.30; Carl Zeiss MicroImag-
ing, Inc.). Images were recorded with a Axiocam and Axiovision software
(Carl Zeiss MicroImaging, Inc.).
Flow cytometry
Cells stained with fluorochrome- or biotin-conjugated surface marker-spe-
cific antibodies (Marsden et al., 2002) were analyzed using a FACScan
(Becton Dickinson). Live and dead cells were discriminated by staining
with 2  g/ml propidium iodide (PI; Sigma-Aldrich). In cell sorting, host-de-
rived (Ly5.1) cells were excluded.
Cell culture
Cells were cultured and T lymphoblasts generated as described previously
(Marsden et al., 2002). Before death assays, the viable cells in stimulated
spleen cultures were enriched by centrifugation over Ficoll-Paque Plus
(Amersham Biosciences). Embryonic fibroblasts, cultured from E14.5 em-
bryos, were used at early passage (n   5).
Cell death assays
For cell death assays, cells were cultured at 0.2–1   10
6 cells/ml and
treated with dexamethasone (Sigma-Aldrich) at 10
–8–10
–6 M,   radiation (5
Gy from a 
60Co source), PMA (Sigma-Aldrich) at 0.1–10 ng/ml, or etopo-
side (VP-16, David Bull Laboratories) at 0.1–100  M. Cell viability was de-
termined by staining with 2  g/ml PI and analysis on a FACScan (Becton
Dickinson). Alternatively, flow cytometry was performed on cells stained
cells with FITC-conjugated Annexin-V. To measure mitochondrial trans-
membrane potential, cultured cells stained for 15 min with 40 nM
3,3 dihexyloxacarbocyanine iodide (DiOC6(3); Molecular Probes) were
subjected to flow cytometry. The caspase inhibitors IDN-1965, IDN-6275
(gifts of K. Tomaselli and T. Oltersdorf, IDUN Pharmaceuticals, San Diego,
CA), Q-VD-OPh (ICN Biomedicals), and zVAD-fmk (Bachem), as well as
the inhibitors zVF-CHO, PD150606, ALLN, ALLM, and z-FG-NHO-Bz-
pOMe (all from Calbiochem), were all solubilized in DMSO. Calpastatin
peptide (Calbiochem) was solubilized in water.
Subcellular fractionation and Western blotting
Subcellular fractionation and Western blotting were performed as de-
scribed previously (Marsden et al., 2002).
Online supplemental material
Western blot analysis of thymocytes (Fig. S1 A) and splenocytes (Fig. S1 B)
from reconstituted animals demonstrates that no compensatory increase in
expression of other caspases was evident in cells lacking caspase-2 and/or
caspase-9.
Combined deficiency of caspases 2 and 9 in thymocytes does not pre-
vent apoptosis in response to a variety of death stimuli. Thymocytes were
subjected to cytokine withdrawal (Fig. S2 A), cultured after graded doses of
  irradation (Fig. S2 B), or treated with dexamethasone, PMA, or etoposide
(Fig. S2, C–H). Caspase-2 deficiency did not influence the sensitivity to
these stimuli of cells lacking or expressing caspase-9.
Western blotting of thymocytes sorted from reconstituted mice demon-
strates that in dying cells the caspase substrates spectrin (Fig. S3 A) and
gelsolin (Fig. S3 B) are processed to the expected caspase-generated prod-
ucts. Cell extracts were also made from cells of the indicated genotypes
cultured with or without the caspase inhibitor IDN-1965. Western blotting
of these extracts shows the caspase dependence of gelsolin processing in
dying cells (Fig. S3 C). Caspase-like DEVDase activity was measured by
fluorogenic assay (Fig. S3 D). Online supplemental material is available at
http://www.jcb.org/cgi/content/full/jcb.200312030/DC1.
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Figure 5. Cytochrome c release and mitochondrial depolarization 
do not require caspases 2 and 9. Ly5.1
 CD4
 8
  thymocytes from 
the reconstituted mice were cultured following 5 Gy   irradiation 
(ir.) (A) Subcellular localization of cytochrome c was determined by 
Western blotting soluble cytosolic (s) and pelleted organelle (p) 
cell fractions (B). Mitochondrial trans-membrane potential was 
determined by FACS analysis of cells stained with 40 nM DiOC6(3). 
The percentages of cells retaining high DiOC6(3) fluorescence are 
shown. Where indicated, cells were cultured in the presence of 
IDN-1965 (100  M).780 The Journal of Cell Biology | Volume 165, Number 6, 2004
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